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Abstract
The advance in nanotechnology has enabled us to utilize particles in the size of the nanoscale. This has created
new therapeutic horizons, and in the case of silver, the currently available data only reveals the surface of the
potential benefits and the wide range of applications. Interactions between viral biomolecules and silver
nanoparticles suggest that the use of nanosystems may contribute importantly for the enhancement of current
prevention of infection and antiviral therapies. Recently, it has been suggested that silver nanoparticles (AgNPs)
bind with external membrane of lipid enveloped virus to prevent the infection. Nevertheless, the interaction of
AgNPs with viruses is a largely unexplored field. AgNPs has been studied particularly on HIV where it was
demonstrated the mechanism of antiviral action of the nanoparticles as well as the inhibition the transmission of
HIV-1 infection in human cervix organ culture. This review discusses recent advances in the understanding of the
biocidal mechanisms of action of silver Nanoparticles.
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Review
Historically, silver metal has been used widely across the
civilizations for different purposes. Many societies use
silver as jewelry, ornamentation and fine cutlery. Silver,
jewelry, wares and cutlery was considered to impart
health benefits to the users. In ancient Indian medical
system (Ayurveda) silver has been described as thera-
peutic agent for many diseases. There is an increasing
use of silver as an efficacious antibacterial and antifungal
agent in wound care products and medical devices [1-4]
including dental work and catheters [5-7]. Another
application is to synthesize composites for use as water
disinfecting filters [8]. Silver is also appearing more fre-
quently in textiles, cosmetics [9], and even domestic
appliances. It is worth mentioning some examples, such
as inorganic composites with a slow silver release rate,
which are currently used as preservatives in a variety of
cosmetic products [10]; another current application
includes new compounds of silica gel microspheres con-
taining a silver thiosulfate complex, which are mixed
into plastics for long-lasting antibacterial protection
[11].
Metallic silver has also been used for surgical prosthe-
sis and splints, fungicides, and coinage. Soluble silver
compounds, such as silver salts, have been used for
treating mental illness, epilepsy, nicotine addiction, gas-
troenteritis, stomatitis [12,13], and sexually transmitted
diseases, including syphilis and gonorrhea [14]. Addi-
tionally, AgNO3, as eye drops, have been utilized to pre-
vent gonococcal ophthalmic neonatorum in newborns
by pediatricians for centuries [15]. Other agents derived
from silver, such as silver sulfadiazine (AgSD) cream,
have been used by surgeons, as topical treatments to
heal burn wounds, for the past 60 years [16,17]. Utiliz-
ing these topical treatments, applied directly to the burn
site, erythema decreased, while the expression of matrix
metalloproteinases (MMPs) increased [18]. Recent
advances in nanotechnology have enabled us to produce
pure silver, as nanoparticles, which are more efficient
than silver ions (AgSD and AgNO3) [19]. This has
opened up whole new strategies to use pure silver
against a wide array of pathogens, particularly multi-
resistant pathogens which are hard to treat with avail-
able antibiotics. The biocidal activities of pure silver
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nanoparticles are discussed in subsequent sections of
this review.
The multi-resistant pathogens due to antigenic shifts
and/or drifts are ineffectively managed with current
medications. This resistance to medication by pathogens
has become a serious problem in public health; there-
fore, there is a strong need to develop new bactericides
and virucides. Silver nanoparticles (AgNPs), having a
long history of general use as an antiseptic and disinfec-
tant, are able to interact with disulfide bonds of the gly-
coprotein/protein contents of microorganisms such as
viruses, bacteria [20,21] and fungi [22]. Both silver nano-
particles and silver ions can change the three dimen-
sional structure of proteins by interfering with S-S
bonds and block the functional operations of the micro-
organism [23,24].
Silver Nanoparticles
Nanoparticles are defined as particulate dispersions or
solid particles with a size in the range of 10-100 nm
[25]. AgNPs can be dissolved in a liquid environment
that prevents their agglomeration or entrapped in a
matrix that utilizes special drug carrier systems (e.g., the
drug is dissolved, entrapped, encapsulated or attached to
a nanoparticle matrix). These particles represent an
interesting candidate for research as microbicides due to
their effectiveness in small doses, minimal toxicity and
side effects [26]. These attributes may contribute signifi-
cantly to the enhancement of current prevention of
infection and antiviral therapies [19,26].
Particle size and size distribution are the most impor-
tant characteristics of nanoparticle systems (Figure 1).
They determine the in vivo distribution, biological fate,
toxicity and the targeting ability of nanoparticle systems
[27]. Available routes of administration include oral,
nasal, parenteral or intra-ocular [28]. Despite these
advantages, nanoparticles do have limitations. For exam-
ple, their small size and large surface area can lead to
particle-particle aggregation, making physical handling
of nanoparticles difficult in liquid and dry forms [29].
This aggregation may lead to the loss of the properties
associated with the nanoscale nature of the particles.
The rate of agglomeration of nanoparticles is an impor-
tant parameter for toxicology studies. Greulich et al.
2009 [30] reported that the agglomeration of AgNPs
was specifically observed after the incubation of AgNPs
in RPMI 1640 medium (a commonly used medium to
dilute AgNPs) alone. However, washing AgNPs with
RPMI 1640 medium containing Fetal Calf Serum (FCS)
efficiently prevented agglomeration of AgNPs. Apart
from agglomeration, particle sizes of AgNPs are also
responsible for cytotoxicity. Yen et al. 2009 reported
that smaller AgNPs (3 nm) are more cytotoxic than lar-
ger particles (25 nm) at a concentration of 10 μg/mL
[31] signifying importance of particle size. Fukuoka and
colleagues in an elegant experiment have demonstrated
synthesis of necklace-shaped mono- and bimetallic
nanowires for organic-inorganic hybrid mesoporous
materials for better efficacy indicating not only the size
of nanoparticle is important, but the shape and mor-
phology are important as well [32]. Recent advances in
Nanotechnology help in modulation of size and shape of
nanoparticles and provide different ways of utilizing
application of nanoparticles in diagnosis and treatment
of various diseases. Using latest technology, Nanomater-
ials can also be tailored to facilitate their applications in
other fields such as bioscience and medicine [3].
AgNPs as Antibacterial Agents
AgNPs are attractive because they are non-toxic to the
human body at low concentrations and have broad-
spectrum antibacterial actions [33]. In fact, it is well
known that Ag+ ions and Ag-based compounds are
toxic to microorganisms, possessing strong biocidal
effects on at least 12 species of bacteria including multi-
resistant bacteria like Methicillin-resistant Staphylococ-
cus aureus (MRSA), as well as multidrug-resistant Pseu-
domonas aeruginosa, ampicillin-resistant E. coli O157:
H7 and erythromycin-resistant S. pyogenes [2,4,21] sug-
gesting that AgNPs are effective broadspectrum [34]
biocides against a variety of drug-resistant bacteria,
which makes them a potential candidate for use in phar-
maceutical products and medical devices that may help
to prevent the transmission of drug-resistant pathogens
in different clinical environments [2,35]. Recently, Meck-
ing and co-workers demonstrated that hybrids of silver
nanoparticles with amphiphilic hyperbranched macro-
molecules exhibited effective antimicrobial surface coat-
ing agent properties [36].
The mechanism of the inhibitory effects of Ag+ ions
on microorganisms is not completely clear, however,
AgNPs interact with a wide range of molecular pro-
cesses within microorganisms resulting in a range of
effects from inhibition of growth, loss of infectivity to
cell death which depends on shape [37], size [31],
Figure 1 Transmission electron microscopy (TEM) images of
silver nanoparticles with diameters of 20 nm (Aldrich), 60 nm
(Aldrich), and 100 nm (Aldrich), respectively. Scale bars are 50
nm.
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concentration of AgNPs [38] and the sensitivity of the
microbial species to silver [2,17,35,39-41]. Several stu-
dies have reported that the positive charge on the Ag+
ion is crucial for its antimicrobial activity through the
electrostatic attraction between the negatively charged
cell membrane of the microorganism and the positively
charged nanoparticles [1]. In contrast, Sondi and Salo-
pek-Sondi reported that the antimicrobial activity of
AgNPs on Gram-negative bacteria depends on the con-
centration of AgNPs and is closely associated with the
formation of pits in the cell wall of bacteria [21]; con-
sequently, AgNPs accumulated in the bacterial mem-
brane disturbing the membrane permeability, resulting
in cell death. However, because those studies included
both positively charged Ag+ ions and negatively
charged AgNPs, this data is insufficient to explain the
antimicrobial mechanism of positively charged silver
nanoparticles. Therefore, we theorize that there is
another possible mechanism. Amro et al. suggested
that metal depletion may cause the formation of irre-
gularly shaped pits in the outer membrane and change
membrane permeability, which is caused by the pro-
gressive release of lipopolysaccharide molecules and
membrane proteins [42]. Also, Sondi and Salopek-
Sondi speculated that a similar mechanism may cause
the degradation of the membrane structure of E. coli
during treatment with AgNPs [21]. Although it is
assumed that AgNPs are involved in some sort of
binding mechanism, the mechanism of the interaction
between AgNPs and components of the outer mem-
brane is still unclear. Recently, Danilczuk and co-work-
ers reported that Ag-generated free radicals derived
from the surface of AgNPs were responsible for the
antimicrobial activity [43]. However, Lara and collea-
gues in another report, proposed another mechanism
of bactericidal action based on the inhibition of cell
wall synthesis, protein synthesis mediated by the 30s
ribosomal subunit, and nucleic acid synthesis [2]. The
proteomic data revealed that a short exposure of E.
coli cells to antibacterial concentrations of AgNPs
resulted in an accumulation of envelope protein pre-
cursors, indicative of the dissipation of proton motive
force [44]. Consistent with these proteomic findings,
AgNPs were shown to destabilize the outer membrane,
collapse the plasma membrane potential and deplete
the levels of intracellular ATP [45].
The mode of action of AgNPs was also found to be
similar to that of Ag+ ions [45]; however, the effective
concentrations of silver nanoparticles and Ag+ ions were
at nanomolar and micromolar levels. Therefore results
in E. coli suggested silver nanoparticles may damage the
structure of bacterial cell membrane and depress the
activity of some membranous enzymes, which cause E.
coli bacteria to die eventually [46].
Silver Nanoparticles as Virucidal Agents
Virucidal agents differ from virustatic drugs in that they
act directly and rapidly by lysing viral membranes on
contact or by binding to virus coat proteins. Neverthe-
less, the interaction of AgNPs with viruses is still an
unexplored field. However, the mechanism of action of
AgNPs as an antiviral and virucidal has been studied
against several enveloped viruses. Recently, it has been
suggested that nanoparticles bind with a viral envelope
glycoprotein and inhibit the virus by binding to the dis-
ulfide bond regions of the CD4 binding domain within
the HIV-1 viral envelope glycoprotein gp120, as sug-
gested by Elechiguerra and colleagues [47]. This fusion
inhibition was later elegantly demonstrated by Lara and
colleagues [19] in their latest report.
The antiviral effects of AgNPs on the hepatitis B virus
(HBV) have been reported using a HepAD38 human
hepatoma cell line. There has been evidence of high
binding affinity of nanoparticles for HBV DNA and
extracellular virions with different sizes (10 and 50 nm).
Moreover, it has been demonstrated that AgNPs could
also inhibit the production of HBV RNA and extracellu-
lar virions in vitro, which was determined using a UV-vs
absorption titration assay. Further investigation will be
needed to determine whether this binding activity pre-
vents HBV virions from entering into host cells or not
[39]. In an another report Sun and colleagues showed
that AgNPs were superior to gold nanoparticles for
cytoprotective activities toward HIV-1-infected Hut/
CCR5 cells [48]. It is generally understood that Ag, in
various forms, inactivates viruses by denaturing enzymes
via reactions with sulfhydra, amino, carboxyl, phosphate,
and imidazole groups [33,34,36,41,49]. However, it is
necessary to design studies in vivo to increase therapeu-
tic benefit and minimize adverse effects.
Among antiviral activities, the capacity of AgNPs to
inhibit an influenza virus was determined in a MDCK
cell culture and was demonstrated that with AgNPs at
0.5 μg/ml concentration viral infectivity was reduced.
Nanosilver may interfere with the fusion of the viral
membrane, inhibiting viral penetration into the host cell
[40].
Lara and colleagues further demonstrated that AgNPs
inhibited a variety of HIV-1 strains regardless of their
tropism, clade and resistance to antiretrovirals [19]. The
fact that AgNPs inhibited number of HIV-1 isolates sug-
gest that their mode of action does not depend on cell
tropism and that AgNPs are broad spectrum anti-HIV-1
agents. A cell-based fusion assay using Env expressing
cells (HL2/3) and CD4 expressing cells mixture demon-
strated that AgNPs efficiently blocked cell-cell fusion in
a dose-dependent manner within the 1.0-2.5 mg/mL
dose range including: Tak-779 (Fusion Inhibitor), AZT
(NRTI), Indinavir (PI) and 118-D-24 (Integrase
Lara et al. Journal of Nanobiotechnology 2011, 9:30
http://www.jnanobiotechnology.com/content/9/1/30
Page 3 of 8
Inhibitor) as controls (Figure 2). In addition, efficient
inhibitory activity of AgNPs against gp120-CD4 interac-
tion was measured in a competitive gp120-capture
ELISA. The results of the cell-based fusion assay con-
firm the hypothesis that AgNPs inhibit HIV-1 infection
by blocking the viral entry, particularly the gp120-CD4
interaction [19]. Other studies also showed that AgNPs
at non-toxic concentrations effectively inhibit arenavirus
replication during the early phases of viral replication
[50].
Continuing to assess antiviral mechanisms, a virus
adsorption assay was performed to measure the
Figure 2 Time-of-addition experiment. HeLa-CD4-LTR-b-gal cells were infected with HIV-1IIIB and exposed to silver nanoparticles (1 mg/mL).
Different antiretrovirals were added at different times post infection. Activity of silver nanoparticles was compared with (A) fusion inhibitor (Tak-
779, 2 μM), (B) RT inhibitor (AZT, 20 μM), (C) protease inhibitor (Indinavir, 0.25 μM), and (D) integrase inhibitor (118-D-24, 100 μM). Dashed lines
indicate the moment when the activity of the silver nanoparticles and the antiretroviral differ. The assays were performed in triplicate; the data
points represent the mean and the colored lines are nonlinear regression curves performed with SigmaPlot 10.0 software. http://www.
jnanobiotechnology.com/content/8/1/1/figure/F2
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inhibitory effects of AgNPs on virus adsorption to
HeLa-CD4-LTR-b-gal cells, which were incubated with
HIVIIIB, in the absence or presence of serial dilutions of
AgNPs. After 2 h of incubation at 37°C, the cells were
extensively washed with 1× PBS to remove the unad-
sorbed virus particles. Then the cells were incubated for
48 h, and the amount of viral infection was quantified
with the Beta-Glo Assay System (Promega). The AgNPs
inhibited the initial stages of the HIV-1 infection cycle
of HIVIIIB virus to cells with an IC50 of 0.44 mg/mL.
Cell-free and cell-associated HIV-1 were pretreated at
different concentrations of AgNPs, and were centrifuged
and washed to separate the virus from the AgNPs and
then infect the indicator cells. The cell-associated virus
includes infected cells that transmit the infection by fus-
ing with non-infected target cells. In addition, AgNPs
treatment of chronically infected H9+ cells as well as
human PBMC+ (cell-associated HIV) resulted in
decreased infectivity in a dose-dependent manner [19].
Time-of-addition experiments (TAE) for HIV revealed
that silver nanoparticles have other sites of intervention
on the viral life cycle besides fusion or entry (Figure 2).
This could be explained by silver nanoparticles suppres-
sing the expression of TNF-a, a cytokine that plays a
critical role in HIV-1 pathogenesis, by incrementing
HIV-1 transcription. The inhibition of the TNF-a acti-
vated transcription might also be a target for the anti-
HIV activity of silver nanoparticles. Having a variety of
targets in the HIV-1 replication cycle makes silver nano-
particles agents that are not prone to contribute to the
emergence of resistant strains [26].
The Antiviral Effect of AgNPs as a Topical Agent on
Human Cervical Tissue
In an experiment evaluating AgNPs application on Human
cervical tissue as an anti-HIV-1 agent, Lara and colleagues
[26] found that AgNPs provided protection against the
transmission of cell-free and cell-associated HIV-1. They
had used an excellent human cervical tissue culture model
to elucidate anti-HIV-1 activity of AgNPs within one min-
ute after the topical treatment on the human cervical tis-
sue (Figure 3). The similar effect was found for 20 minutes
time point of topical pretreatment and washing of the
AgNPs. The human cervical tissue culture remained pro-
tected against infection with HIV-1 for as long as 48 h,
demonstrating a long-lasting tissue protection afforded by
AgNPs. This lasting protection is necessary for a topical
vaginal microbicide to ensure safety against infection even
for many hours after gel application and, even more
importantly, after the gel is washed away (Figure 4) [26].
AgNPs as Topical Agents in Mucosal Human Tissue
Recent studies showed that pre-treatment of human cer-
vical tissues with AgNPs increased the proliferation of
lymphocytes, presumably due to activation of the
immune cells [26,14,51,52]. The increased proliferation
of lymphocytes also increases inflammatory process in
situ by contributing in wound healing in vivo [53]. The
development of inflammatory process in cervical tissue
helps activation of innate defenses against invading
microbes. These changes during inflammation in cervi-
cal tissue are chiefly regulated under hormonal condi-
tions by estradiol and progesterone [54,55]. Further
studies are necessary to evaluate topical use of nanopar-
ticles applied repeatedly to record chronic response,
toxicity (i.e., genetic, reproductive, and carcinogenic
toxicities) and long-term side effects, susceptibility to
opportunistic infections or significant changes in tissue
architecture. Studies should also be performed to evalu-
ate occurrence of any hypersensitivity/photosensitivity
and AgNPs effect on condom integrity before AgNPs
can be included in a topical gel for human use [56,57].
AgNPs cytotoxicity
The AgNPs have been shown to be cytotoxic at higher
concentration than 6 μg/mL. Hsin and colleagues pro-
vided evidence for the molecular mechanism of AgNPs
induction of cytotoxicity. They showed that AgNPs
acted through ROS and JNK to induce apoptosis via
the mitochondrial pathway in NIH3T3 fibroblast cells
[58]. Park and colleagues reported cytotoxicity using
Figure 3 Human cervical culture model. a) To rule out possible
leaks in the agarose seal, Dextran blue was added to the upper
chamber on day 6 of the culture. Its presence in the lower chamber
was determined 20 h later to all Transwells used in the experiments,
along with the negative control well with agarose only, b) the other
negative control alone, with tissue and virus but without treatment
or challenge and c) positive control well with tissue alone, infected
with only the HIV-1 virus. d) Inhibition of HIV-1 transmission; the
cervical tissue was treated with PVP-coated AgNPs at different
concentrations in a Replens gel or RPMI + 10% FCS media, which
was then infected with HIV-1IIIB. HIV transmission or inhibition of
transmission across the mucosa was determined in the lower
chamber by formation of syncytia using indicator cells (MT-2).
http://www.jnanobiotechnology.com/content/8/1/15/figure/F3
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silver nanoparticles prepared by dispersing them in
fetal bovine serum, as a biocompatible material, on a
cultured macrophage cell line, which induced cellular
apoptosis [59]. Furthermore, AgNPs decreased intracel-
lular glutathione levels, increased NO secretion,
increased TNF-a protein and gene levels, and
increased the gene expression of matrix metalloprotei-
nases, such as MMP-3, MMP-11, and MMP-19. Kim
and colleagues demonstrated cytotoxicity induced by
AgNPs in human hepatoma HepG2 cells and observed
that AgNPs agglomerated in the cytoplasm and nuclei
of treated cells, and induced intracellular oxidative
stress, independent of the toxicity of the Ag+ ions [1].
In a similar study, Kawata and colleagues showed an
upregulation of DNA repair-associated genes in hepa-
toma cells cultured with low dose AgNPs, suggesting
possible DNA damaging effects [60,61]. Recent studies
demonstrated that uptake of AgNPs occurs mainly
through clathrin mediated endocytosis and macropino-
cytosis [38], however it seems that AgNPs have multi-
ples cellular targets that vary among different cell
types.
Figure 4 Protection from HIV-1 infection following pre-treatment of the cervical explant with PVP-coated AgNPs. a) Cervical explants
were exposed to 0.1 or 0.15 mg/mL PVP-coated AgNPs in RPMI + 10% FCS media for 20 minutes. After thoroughly washing extracellular PVP-
coated AgNPs from the cervical explant, and after 1 minute, 24 h, 48 h and 72 h, cell-free virus (HIV-1IIIB) [(5 × 10
5 TCID50)] was added to the
upper chamber. To verify the neutralization of HIV-1 transmission, we cultured the indicator cells (MT-2) in the lower chamber and evaluated the
inhibition of the HIV-1 infection. b) Cervical explants were exposed to HIV-1 in the absence of PVP-coated AgNPs as a control and to 0.1 or 0.15
mg/mL of PVP-coated AgNPs as pretreatment. Graphs show values of the means ± standard deviations from three separate experiments. Graphs
were created using the SigmaPlot 10.0 software. http://www.jnanobiotechnology.com/content/8/1/15/figure/F5
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Conclusions
The emergence and spread of antibiotic resistance
pathogen is an alarming concern in clinical practice.
Many organisms such as MRSA, HIV-1, Hepatitis-B
Virus, and Ampicillin resistant E.coli are difficult to
treat. There is a need of a cheap broad-active agent that
can be used against variety of pathogen. The AgNPs
have been found to be effective against many viruses
and bacterial species. The use of noble metals at nano-
sizes to treat many conditions is gaining importance.
The recent development in nanotechnology has pro-
vided tremendous impetus in this direction due to its
capacity of modulating metals into nanosizes and var-
ious shapes, which drastically changes the chemical,
physical and optical properties and their use. The effi-
cacy of AgNPs against HIV-1 has been reported by
many laboratories including ours [19,26]. It has been
shown that AgNPs have got anti-HIV-1 activity and can
help the host immune system against HIV-1. This has
laid ground for the development of new, potent antiviral
drugs capable of preventing HIV infection and control-
ling virus replication. Recently, it has been demonstrated
that AgNPs function as broad-spectrum virucidal and
bactericidal agents, and in addition, increase wound
healing. Nonetheless, conclusive safety has not been
demonstrated extensively in animal models, and there-
fore, additional testing of AgNPs is needed before they
can be used in clinical applications.
Authors Information
DKS: is an associate professor of microbiology at the Winston Salem State
University. DKS’ lab is working on development of a DNA vaccine for HIV/
AIDS. His other research interest involves prevention of HIV-1 transmission at
the cervical/vaginal mucosal surfaces. His current research is funded by two
NIH grants.
Acknowledgements
The work described was supported by Award Number P20MD002303 from
the National Center on Minority Health and Health Disparities, and
SC3GM084802 from National Institute of General Medical Sciences of NIH to
DKS. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Center on Minority
Health and Health Disparities or NIGMS or the National Institutes of Health.
This research is a project supported by Winston-Salem State University’s
Center of Excellence for the Elimination of Health Disparities.
Author details
1Department of Life Sciences, Winston-Salem State University, Winston
Salem, NC 27110, USA. 2Laboratorio de Terapia Celular, Departamento de
Bioquimica y Medicina Molecular, Facultad de Medicina Universidad
Autonoma de Nuevo Leon, Mexico.
Authors’ contributions
All authors read and approved the final manuscript. HHL participated in
AgNPs cytotoxicity, AgNPs as topical agents in mucosal human tissue, and
overall design of this review article. ENGT participated in AgNPs as
antibacterial agent portion of this review, and overall design of this review
article along with HHL. LIT participated in antiviral effect of AgNPs as a
topical agent on Human cervical tissue. DKS participated in AgNPs as
virucidal agents, and editing and revision of this report. His lab provided
materials and resources used in this study.
Competing interests
The authors declare that they have no competing interests.
Received: 11 May 2011 Accepted: 3 August 2011
Published: 3 August 2011
References
1. Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, Lee HJ, Kim SH, Park YK, Park YH,
Hwang CY, Kim YK, Lee YS, Jeong DH, Cho MH: Antimicrobial effects of
silver nanoparticles. Nanomedicine 2007, 3:95-101.
2. Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C:
Bactericidal effect of silver nanoparticles against multidrug-resistant
bacteria. World Journal of Microbiology and Biotechnology 2010, 26:615-621.
3. Salata O: Applications of nanoparticles in biology and medicine. J
Nanobiotechnology 2004, 2:3.
4. Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S: Synthesis and effect of
silver nanoparticles on the antibacterial activity of different antibiotics
against Staphylococcus aureus and Escherichia coli. Nanomedicine 2007,
3:168-171.
5. Catauro M, Raucci MG, De GF, Marotta A: Antibacterial and bioactive
silver-containing Na2O × CaO × 2SiO2 glass prepared by sol-gel
method. J Mater Sci Mater Med 2004, 15:831-837.
6. Crabtree JH, Burchette RJ, Siddiqi RA, Huen IT, Hadnott LL, Fishman A: The
efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-
related infections. Perit Dial Int 2003, 23:368-374.
7. Khare MD, Bukhari SS, Swann A, Spiers P, McLaren I, Myers J: Reduction of
catheter-related colonisation by the use of a silver zeolite-impregnated
central vascular catheter in adult critical care. J Infect 2007, 54:146-150.
8. Jain P, Pradeep T: Potential of silver nanoparticle-coated polyurethane
foam as an antibacterial water filter. Biotechnol Bioeng 2005, 90:59-63.
9. Lansdown AB: A pharmacological and toxicological profile of silver as an
antimicrobial agent in medical devices. Adv Pharmacol Sci 2010,
2010:910686.
10. Kokura S, Handa O, Takagi T, Ishikawa T, Naito Y, Yoshikawa T: Silver
nanoparticles as a safe preservative for use in cosmetics. Nanomedicine
2010, 6:570-574.
11. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramirez JT,
Yacaman MJ: The bactericidal effect of silver nanoparticles.
Nanotechnology 2005, 16:2346-2353.
12. Alidaee MR, Taheri A, Mansoori P, Ghodsi SZ: Silver nitrate cautery in
aphthous stomatitis: a randomized controlled trial. Br J Dermatol 2005,
153:521-525.
13. Tanweer F, Hanif J: Re: Silver nitrate cauterisation, does concentration
matter? Clin Otolaryngol 2008, 33:503-504.
14. Gougeon ML, Lecoeur H, Dulioust A, Enouf MG, Crouvoiser M, Goujard C,
Debord T, Montagnier L: Programmed cell death in peripheral
lymphocytes from HIV-infected persons: increased susceptibility to
apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation
and with disease progression. J Immunol 1996, 156:3509-3520.
15. Hoyme UB: Clinical significance of Crede’s prophylaxis in germany at
present. Infect Dis Obstet Gynecol 1993, 1:32-36.
16. George N, Faoagali J, Muller M: Silvazine (silver sulfadiazine and
chlorhexidine) activity against 200 clinical isolates. Burns 1997,
23:493-495.
17. Illingworth B, Bianco RW, Weisberg S: In vivo efficacy of silver-coated
fabric against Staphylococcus epidermidis. J Heart Valve Dis 2000,
9:135-141.
18. Hoffmann S: Silver sulfadiazine: an antibacterial agent for topical use in
burns. A review of the literature. Scand J Plast Reconstr Surg 1984,
18:119-126.
19. Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, Rodriguez-Padilla C: Mode of
antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology
2010, 8:1.
20. Furr JR, Russell AD, Turner TD, Andrews A: Antibacterial activity of Actisorb
Plus, Actisorb and silver nitrate. J Hosp Infect 1994, 27:201-208.
21. Sondi I, Salopek-Sondi B: Silver nanoparticles as antimicrobial agent: a
case study on E. coli as a model for Gram-negative bacteria. J Colloid
Interface Sci 2004, 275:177-182.
22. Gajbhiye M, Kesharwani J, Ingle A, Gade A, Rai M: Fungus-mediated
synthesis of silver nanoparticles and their activity against pathogenic
fungi in combination with fluconazole. Nanomedicine 2009, 5:382-386.
Lara et al. Journal of Nanobiotechnology 2011, 9:30
http://www.jnanobiotechnology.com/content/9/1/30
Page 7 of 8
23. Chung YC, Chen IH, Chen CJ: The surface modification of silver
nanoparticles by phosphoryl disulfides for improved biocompatibility
and intracellular uptake. Biomaterials 2008, 29:1807-1816.
24. Liau SY, Read DC, Pugh WJ, Furr JR, Russell AD: Interaction of silver nitrate
with readily identifiable groups: relationship to the antibacterial action
of silver ions. Lett Appl Microbiol 1997, 25:279-283.
25. Zhang G, Niu A, Peng S, Jiang M, Tu Y, Li M, Wu C: Formation of novel
polymeric nanoparticles. Acc Chem Res 2001, 34:249-256.
26. Lara HH, Ixtepan-Turrent L, Garza-Trevino EN, Rodriguez-Padilla C: PVP-
coated silver nanoparticles block the transmission of cell-free and cell-
associated HIV-1 in human cervical culture. J Nanobiotechnology 2010,
8:15.
27. Panyam J, Labhasetwar V: Biodegradable nanoparticles for drug and gene
delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347.
28. Mohanraj VJ, Chen Y, (Eds): Nanoparticles. J Pharmaceutical Research 2006,
5:561-573.
29. Kondow T, Mafune F: Structures and dynamics of molecules on liquid
beam surfaces. Annu Rev Phys Chem 2000, 51:731-761.
30. Greulich C, Kittler S, Epple M, Muhr G, Koller M: Studies on the
biocompatibility and the interaction of silver nanoparticles with human
mesenchymal stem cells (hMSCs). Langenbecks Arch Surg 2009,
394:495-502.
31. Yen HJ, Hsu SH, Tsai CL: Cytotoxicity and immunological response of
gold and silver nanoparticles of different sizes. Small 2009, 5:1553-1561.
32. Fukuoka A, Sakamoto Y, Guan S, Inagaki S, Sugimoto N, Fukushima Y,
Hirahara K, Iijima S, Ichikawa M: Novel templating synthesis of necklace-
shaped mono- and bimetallic nanowires in hybrid organic-inorganic
mesoporous material. J Am Chem Soc 2001, 123:3373-3374.
33. Baker C, Pradhan A, Pakstis L, Pochan DJ, Shah SI: Synthesis and
antibacterial properties of silver nanoparticles. J Nanosci Nanotechnol
2005, 5:244-249.
34. Rai M, Yadav A, Gade A: Silver nanoparticles as a new generation of
antimicrobials. Biotechnol Adv 2009, 27:76-83.
35. Yamanaka M, Hara K, Kudo J: Bactericidal actions of a silver ion solution
on Escherichia coli, studied by energy-filtering transmission electron
microscopy and proteomic analysis. Appl Environ Microbiol 2005,
71:7589-7593.
36. Aymonier C, Schlotterbeck U, Antonietti L, Zacharias P, Thomann R, Tiller JC,
Mecking S: Hybrids of silver nanoparticles with amphiphilic
hyperbranched macromolecules exhibiting antimicrobial properties.
Chem Commun (Camb) 2002, 3018-3019.
37. Pal S, Tak YK, Song JM: Does the antibacterial activity of silver
nanoparticles depend on the shape of the nanoparticle? A study of the
Gram-negative bacterium Escherichia coli. Appl Environ Microbiol 2007,
73:1712-1720.
38. Asharani PV, Hande MP, Valiyaveettil S: Anti-proliferative activity of silver
nanoparticles. BMC Cell Biol 2009, 10:65.
39. Lu L, Sun RW, Chen R, Hui CK, Ho CM, Luk JM, Lau GK, Che CM: Silver
nanoparticles inhibit hepatitis B virus replication. Antivir Ther 2008,
13:253-262.
40. Mehrbod P, Motamed N, Tabatabaian M, Soleimani Estyar R, Amini E,
Shahidi M: In Vitro Antiviral Effect of “Nanosilver” on Influenza Virus.
DARU 2009, 17:88-93.
41. Ruparelia JP, Chatterjee AK, Duttagupta SP, Mukherji S: Strain specificity in
antimicrobial activity of silver and copper nanoparticles. Acta Biomater
2008, 4:707-716.
42. Amro NA, Kotra LP, Wadu-Mesthrige K, Bulychev A, Mobashery S, Liu G,
(Eds): High-resolution atomic force microscopy studies of the Escherichia
coli outer membrane: structural basis for permeability. Langmuir 2000,
16:2789-2796.
43. Danilczuk M, Lund A, Sadlo J, Yamada H, Michalik J: Conduction electron
spin resonance of small silver particles. Spectrochim Acta A Mol Biomol
Spectrosc 2006, 63:189-191.
44. Lok CN, Ho CM, Chen R, He QY, Yu WY, Sun H, Tam PK, Chiu JF, Che CM:
Proteomic analysis of the mode of antibacterial action of silver
nanoparticles. J Proteome Res 2006, 5:916-924.
45. Dibrov P, Dzioba J, Gosink KK, Hase CC: Chemiosmotic mechanism of
antimicrobial activity of Ag(+) in Vibrio cholerae. Antimicrob Agents
Chemother 2002, 46:2668-2670.
46. Li WR, Xie XB, Shi QS, Zeng HY, Ou-Yang YS, Chen YB: Antibacterial activity
and mechanism of silver nanoparticles on Escherichia coli. Appl Microbiol
Biotechnol 2010, 85:1115-1122.
47. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH,
Yacaman MJ: Interaction of silver nanoparticles with HIV-1. J
Nanobiotechnology 2005, 3:6.
48. Sun RW, Chen R, Chung NP, Ho CM, Lin CL, Che CM: Silver nanoparticles
fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1
infected cells. Chem Commun (Camb) 2005, 5059-5061.
49. Borkow G, Gabbay J: Putting copper into action: copper-impregnated
products with potent biocidal activities. FASEB J 2004, 18:1728-1730.
50. Speshock JL, Murdock RC, Braydich-Stolle LK, Schrand AM, Hussain SM:
Interaction of silver nanoparticles with Tacaribe virus. J
Nanobiotechnology 2010, 8:19.
51. Poon VK, Burd A: In vitro cytotoxity of silver: implication for clinical
wound care. Burns 2004, 30:140-147.
52. Wright JB, Lam K, Buret AG, Olson ME, Burrell RE: Early healing events in a
porcine model of contaminated wounds: effects of nanocrystalline silver
on matrix metalloproteinases, cell apoptosis, and healing. Wound Repair
Regen 2002, 10:141-151.
53. Tian J, Wong KK, Ho CM, Lok CN, Yu WY, Che CM, Chiu JF, Tam PK: Topical
delivery of silver nanoparticles promotes wound healing. ChemMedChem
2007, 2:129-136.
54. Fahey JV, Wright JA, Shen L, Smith JM, Ghosh M, Rossoll RM, Wira CR:
Estradiol selectively regulates innate immune function by polarized
human uterine epithelial cells in culture. Mucosal Immunol 2008,
1:317-325.
55. Wira CR, Fahey JV: The innate immune system: gatekeeper to the female
reproductive tract. Immunology 2004, 111:13-15.
56. Cremel M, Berlier W, Hamzeh H, Cognasse F, Lawrence P, Genin C,
Bernengo JC, Lambert C, Dieu-Nosjean MC, Delézay O: Characterization of
CCL20 secretion by human epithelial vaginal cells: involvement in
Langerhans cell precursor attraction. J Leukoc Biol 2005, 78:158-166.
57. McGowan I: Microbicides: a new frontier in HIV prevention. Biologicals
2006, 34:241-255.
58. Hsin YH, Chen CF, Huang S, Shih TS, Lai PS, Chueh PJ: The apoptotic effect
of nanosilver is mediated by a ROS- and JNK-dependent mechanism
involving the mitochondrial pathway in NIH3T3 cells. Toxicol Lett 2008,
179:130-139.
59. Park EJ, Yi J, Kim Y, Choi K, Park K: Silver nanoparticles induce cytotoxicity
by a Trojan-horse type mechanism. Toxicol In Vitro 2010, 24:872-878.
60. Kawata K, Osawa M, Okabe S: In vitro toxicity of silver nanoparticles at
noncytotoxic doses to HepG2 human hepatoma cells. Environ Sci Technol
2009, 43:6046-6051.
61. Miura N, Shinohara Y: Cytotoxic effect and apoptosis induction by silver
nanoparticles in HeLa cells. Biochem Biophys Res Commun 2009,
390:733-737.
doi:10.1186/1477-3155-9-30
Cite this article as: Lara et al.: Silver nanoparticles are broad-spectrum
bactericidal and virucidal compounds. Journal of Nanobiotechnology 2011
9:30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lara et al. Journal of Nanobiotechnology 2011, 9:30
http://www.jnanobiotechnology.com/content/9/1/30
Page 8 of 8
